Avidity Biosciences — Investor Day (September 2025)
24 slides from Avidity Biosciences's investor day presentation, Sep 10, 2025
Slide 1: Investor & Analyst Event: Redefining the Treatment of DMD
1 September 10, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Redefining the Treatment of Duchenne Muscular Dystrophy (DMD) Del-zota EXPLORE44-OLE Topline and Functional Data Exhibit 99.1
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking state
Slide 3: Our Vision
3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Yannick, living with DMD
Slide 4: Today's Presenters
4Redefining the Treatment of DMD Today’s Presenters Sarah Boyce President & CEO Steve Hughes, MD Chief Medical Officer
Slide 5: Three Programs Moving to Commercialization
5 Three Programs Moving to Commercialization Lee Living with DMD, and his mother, Ginne Jeannine Living with DM1 Russell Living with FSHD Delpacibart etedesiran (Del-desiran) in DM1 • ~80,000 patients in U.S. and Europe • On track to be the first globally approved drug for DM1 Delpacibart braxlosira
Slide 6: DMD: Hereditary Disorder Causing Progressive, Debilitating Muscle Damage
6 DMD: Hereditary Disorder Causing Progressive, Debilitating Muscle Damage and Significantly Reduced Life Expectancy • Monogenic, X-linked, recessive condition characterized by progressive muscle damage and weakness • Primarily affects males, loss of ambulation by teenage years • Significantly reduc
Slide 7: Today's Update
7 Today’s Update Unprecedented functional improvement on all key measures demonstrated at one year across EXPLORE44® & EXPLORE44-OLE Compelling biomarker data of muscle health including rapid, significant and sustained creatine kinase (CK) reductions Continued favorable safety and tolerability with
Slide 8: Agenda/Outline
8 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Del-zota: Redefining the Treatment of DMD Steve Hughes, M.D., CMO Closing Remarks Sarah Boyce, President & CEO Q&A Session Avidity Management Moderator: Kat Lange, CBO
Slide 9: Key Information Across EXPLORE44 and EXPLORE44-OLE
9 Key Information Across EXPLORE44® and EXPLORE44-OLE 1. Doses expressed as PMO component. 2. Participants at 10 mg/kg Q8W in EXPLORE44 were transitioned to 5 mg/kg Q6W. Q6W, every 6 weeks; Q8W, every 8 weeks. EXPLORE44® Key Information • Randomized, double-blind, placebo controlled • Two cohorts: 5
Slide 10: Del-zota Continues to Demonstrate Favorable Long-Term Safety and Tolerability
10 EXPLORE44-OLE Del-zota Continues to Demonstrate Favorable Long-Term Safety and Tolerability Total Participants N=39 Any AE 33 (85%) Related to study drug 10 (26%) Serious AE 3 (8%) Serious AE related to study drug 1 (3%) AE leading to treatment discontinuation 1 (3%) AE leading to death 0 In the
Slide 11: Del-zota Designed to Facilitate Exon Skipping to Produce Near Full-length Dystrophin
11 Del-zota is Designed to Facilitate Exon Skipping to Produce Functional, Near Full-length Dystrophin Naturally occurring dystrophin Representative dystrophin produced by del-zota Representative micro-dystrophin produced by gene therapies N H1 R1 R2 R3 H2 R 24 H4 CR N H1 R1 R2 R3 H2 R4 R5 R6 R7 R8
Slide 12: Del-zota Demonstrated Unprecedented Increase in Dystrophin
12 Del-zota Demonstrated Unprecedented Increase in Dystrophin 1. Not adjusted for muscle content. Dystrophin protein in biceps brachii was measured by western blot and normalized to myosin heavy chain. Mean ± SEM. Dystrophin <1% (BLQ) was imputed as zero (*p<0.05, Wilcoxon test). 2. Magnification 20
Slide 13: Del-zota Provided Long-term Protection from Muscle Damage
13 Del-zota Provided Long-term Protection from Muscle Damage Creatine kinase levels rapidly reduced by > 80% compared to baseline and sustained at near normal levels 50% of participants had CK levels within normal range at 1 year of treatment Upper limit of normal (ULN) shown is 251 and is dependent
Slide 14: Baseline Characteristics: Del-zota vs DMD44 Natural History
14 1. Natural History (Nat Hx) data from PRO-DMD-01 database (CureDuchenne), analyzed by Analysis Group®. Data shown are means. 2. 12 ambulatory participants eligible through ~1 year. One participant excluded due to ankle sprain prior to 1-year assessment and one participant unable to complete asses
Slide 15: 4-Stair Climb: Improvement vs Natural History at ~1 Year
15 4-Stair Climb: Improvement in del-zota Treated Participants Compared to Natural History at ~1 Year 4-Stair Climb DMD44 Nat Hx N=22 Del-zota N=10 Change in Seconds All del-zota data shown in this presentation is as of the June 2025 data cutoff date. All data shown are mean change (±SEM) from Basel
Slide 16: 10m Walk/Run Test: Improvement vs Natural History at ~1 Year
16 10m Walk/Run Test: Improvement in del-zota Treated Participants Compared to Natural History at ~1 Year 10MWRT DMD44 Nat Hx N=22 Del-zota N=10 Change in Seconds All del-zota data shown in this presentation is as of the June 2025 data cutoff date. All data shown are mean change (±SEM) from Baseline
Slide 17: Time to Rise from Floor: Improvement vs Natural History at ~1 Year
17 Time to Rise from Floor: Improvement in del-zota Treated Participants Compared to Natural History at ~1 Year TTR DMD44 Nat Hx N=19 Del-zota N=6 Change in Seconds All del-zota data shown in this presentation is as of the June 2025 data cutoff date. All data shown are mean change (±SEM) from Baseli
Slide 18: NSAA Scores: Improvement vs Natural History at ~1 Year
18 NSAA Scores: Improvement in del-zota Treated Participants Compared to Natural History at ~1 Year NSAA DMD44 Nat Hx N=20 Del-zota N=10 Change in Total Score All del-zota data shown in this presentation is as of the June 2025 data cutoff date. All data shown are mean change (±SEM) from Baseline to
Slide 19: Performance of Upper Limb: Improvement vs Natural History at ~1 Year
19 Performance of Upper Limb (PUL): Improvement in del-zota Treated Participants Compared to Natural History at ~1 Year All del-zota data shown in this presentation is as of the June 2025 data cutoff date. All data shown are mean change (±SEM) from Baseline to ~1 year. 5 mg/kg and 10 mg/kg treatment
Slide 20: Del-zota Has Shown Improvement Across Key Functional Endpoints at ~1 Year
20 Del-zota Has Shown Improvement Across Key Functional Endpoints at ~1 Year of Treatment • Statistically-significant dystrophin increase delivering sustained improvements in CK and muscle protection • Consistent, clinically meaningful improvements across functional endpoints at ~1 year • Favorable
Slide 21: Agenda/Outline
21 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Del-zota: Redefining the Treatment of DMD Steve Hughes, M.D., CMO Closing Remarks Sarah Boyce, President & CEO Q&A Session Avidity Management Moderator: Kat Lange, CBO
Slide 22: Revolutionizing RNA Delivery
22 Revolutionizing RNA Delivery Key Participant Characteristics (N = 39) Ages 7 – 27, mean age 13 Ambulatory (67%) and non- ambulatory (33%) 90% on steroids REDEFINING DMD UNMATCHED COMMITMENT ACCELERATED PATHWAY • Unprecedented functional improvements and reversal of disease progression vs natural
Slide 23: Redefining the Treatment of DMD: Q&A
23Redefining the Treatment of DMD Sarah Boyce President & CEO Steve Hughes, MD Chief Medical Officer W. Michael Flanagan, PhD Chief Scientific Officer Q&A Kat Lange Chief Business Officer
Slide 24: Our Vision
24 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Nathan, living with DMD, and his mother, Misty